Xcell Therapeutics Inc. (KOSDAQ:373110)

South Korea flag South Korea · Delayed Price · Currency is KRW
3,410.00
+110.00 (3.33%)
Jul 18, 2025, 3:30 PM KST
-59.74%
Market Cap37.30B
Revenue (ttm)1.74B
Net Income (ttm)-9.83B
Shares Out10.94M
EPS (ttm)-940.94
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume257,966
Average Volume168,676
Open3,300.00
Previous Close3,300.00
Day's Range3,230.00 - 3,590.00
52-Week Range3,105.00 - 9,760.00
Betan/a
RSI59.46
Earnings DateAug 14, 2025

About Xcell Therapeutics

Xcell Therapeutics Inc. engages in the development and production of drugs for cell therapy. It offers CellCor, a serum-free chemically defined medium that is used to develop human mesenchymal stem cells. Xcell Therapeutics Inc. was incorporated in 2015 and is based in Seoul, South Korea. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 67
Stock Exchange KOSDAQ
Ticker Symbol 373110
Full Company Profile

Financial Performance

In 2024, Xcell Therapeutics's revenue was 1.93 billion, an increase of 72.11% compared to the previous year's 1.12 billion. Losses were -9.54 billion, 2.83% more than in 2023.

Financial Statements

News

There is no news available yet.